Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 34,340	$ 9,298	$ 64,215	$ 17,346
General and administrative	4,191	2,979	11,797	5,076
Total operating expenses	38,531	12,277	76,012	22,422
Loss from operations	(38,531)	(12,277)	(76,012)	(22,422)
Other income (expense), net	(306)	10	(26)	5
Net loss	$ (38,837)	$ (12,267)	$ (76,038)	$ (22,417)
Net loss per share, basic (in dollars per share)	$ (1.67)	$ (0.53)	$ (3.27)	$ (2.67)
Net loss per share, diluted (in dollars per share)	$ (1.67)	$ (0.53)	$ (3.27)	$ (2.67)
Weighted average common shares outstanding, basic (in shares)	23,290,249	23,114,715	23,255,343	8,402,277
Weighted average common shares outstanding, diluted (in shares)	23,290,249	23,114,715	23,255,343	8,402,277